Select Page

Cancer Drug Development company in Europe for sale

  • Size: medium – size
  • Location of this manufacturer: Eastern Europe
  • Sales: <2 million EUR
  • #CFIE PHS026

Overview of this cancer drug development company

The owner of a contract research organization located in Eastern Europe decided to sell the business. The business is operated by experts who have affluent knowledge in developing new pharmaceutical products for the treatment and prevention of tumorous and metabolic diseases. The business primarily focuses on research and drug development related to deuterium depletion. Deuterium depletion also known as light water, is water with lower concentration of deuterium than naturally.

Profile (strategy) of this cancer drug development company

This company for sale is a drug development and cancer research company with sales around 2 million euro, situated in Eastern Europe. The company has a well-defined concept to develop new drugs based on deuterium depletion and effective drugs for different indications. It is not a new company on the market. The company was established in 19 and gained 25 years of experience in the research of deuterium depletion. Deuterium depletion also known as light water, is water which has a lower concentration of deuterium than naturally.

Currently employs 12 workers and has an exclusive partnership in given territory.

On top of that, it can also offer strong IP position and good reputation – has been selling products in more than 40 countries worldwide. The research made by the company resulted in developing new products which are now available on the market. Some of the products are: deuterium-depleted drinking waters for human consumption and anticancer medicinal product for veterinary use. Targets for deuterium depletion: cancer, diabetes, high blood pressure, disease of lipid metabolism, prevention.

The company is looking for:

Distributors for marketing and selling their products worldwide

Investors to launch Phase 2 clinical trials for different tumor types

License partners

Subscribe as an interested buyer
Contact us to get details about this cancer drug development company in eastern europe for sale

Activities and products of this cancer drug development company

The company is developing new drugs based on deuterium depletion and effective drugs for different indications.

Has been selling products in more than 40 countries worldwide.

Developing and registering pharmaceutical and consumers products primarily for the treatment and prevention of tumorous and metabolic diseases.

Opening up new ways of application of the method in further ranges of indication.

Researching and inventing new ways how deuterium depletion can be used in treatment of cancer, diabetes, blood pressure, lipid metabolism and prevention.

 

 Highlights of the cancer drug development company

  • It is a special contract research organization run by skilled experts.
  • These highly skilled workers have rich experiences in developing new pharmaceutical products for the treatment and prevention of tumorous and metabolic diseases.
  • Has been selling products in more than 40 countries worldwide.
  • Some of the products are: deuterium-depleted drinking waters for human consumption and anticancer medicinal product for veterinary use.
  • The company is actively looking for: distributors, investors to launch Phase 2 clinical trials for different tumor types, licensed partners

More information on this cancer drug development company in eastern europe for sale

Please get in touch if you are interested in learning more about this cancer drug development company in eastern europe for sale. For more cmo companies for sale please visit the section cmo companies for sale. For other cmo buyers, please visit the section cmo companies wanted. If you are instead interested in pharma companies for sale, please visit the pharma companies for sale section. For pharma buyers, please visit the section pharma companies wanted.

Subscribe as an interested buyer for this CMO company for sale

Privacy(Required)
en_GBEnglish (UK)